NEW YORK (GenomeWeb) – While lab industry groups expressed disappointment at the Centers for Medicare & Medicaid Services’ preliminary 2018 prices for clinical lab tests under the Protecting Access to Medicare Act, the reaction of the stock markets Monday indicated that not all labs equally shared the pain.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.